FDA Panel Gives Thumbs Down to Oral Drug for NSCLC With Rare HER2 Mutations
Panel decides benefits of poziotinib do not outweigh risks despite 'clear' unmet need
Source: medpagetoday.com
Stay updated with breaking news from She Chia Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Panel decides benefits of poziotinib do not outweigh risks despite 'clear' unmet need